• Something wrong with this record ?

Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling

M. Turi, A. Anilkumar Sithara, L. Hofmanová, D. Žihala, D. Radhakrishnan, A. Vdovin, S. Knápková, T. Ševčíková, Z. Chyra, T. Jelínek, M. Šimíček, A. Gullà, KC. Anderson, R. Hájek, M. Hrdinka

. 2023 ; 24 (6) : . [pub] 20230315

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23003793

During innate immune responses, myeloid differentiation primary response 88 (MyD88) functions as a critical signaling adaptor protein integrating stimuli from toll-like receptors (TLR) and the interleukin-1 receptor (IL-1R) family and translates them into specific cellular outcomes. In B cells, somatic mutations in MyD88 trigger oncogenic NF-κB signaling independent of receptor stimulation, which leads to the development of B-cell malignancies. However, the exact molecular mechanisms and downstream signaling targets remain unresolved. We established an inducible system to introduce MyD88 to lymphoma cell lines and performed transcriptomic analysis (RNA-seq) to identify genes differentially expressed by MyD88 bearing the L265P oncogenic mutation. We show that MyD88L265P activates NF-κB signaling and upregulates genes that might contribute to lymphomagenesis, including CD44, LGALS3 (coding Galectin-3), NFKBIZ (coding IkBƺ), and BATF. Moreover, we demonstrate that CD44 can serve as a marker of the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) and that CD44 expression is correlated with overall survival in DLBCL patients. Our results shed new light on the downstream outcomes of MyD88L265P oncogenic signaling that might be involved in cellular transformation and provide novel therapeutical targets.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003793
003      
CZ-PrNML
005      
20230425140904.0
007      
ta
008      
230418s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms24065623 $2 doi
035    __
$a (PubMed)36982699
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Turi, Marcello $u Faculty of Science, University of Ostrava, 70100 Ostrava, Czech Republic $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic $1 https://orcid.org/0000000287601794
245    10
$a Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling / $c M. Turi, A. Anilkumar Sithara, L. Hofmanová, D. Žihala, D. Radhakrishnan, A. Vdovin, S. Knápková, T. Ševčíková, Z. Chyra, T. Jelínek, M. Šimíček, A. Gullà, KC. Anderson, R. Hájek, M. Hrdinka
520    9_
$a During innate immune responses, myeloid differentiation primary response 88 (MyD88) functions as a critical signaling adaptor protein integrating stimuli from toll-like receptors (TLR) and the interleukin-1 receptor (IL-1R) family and translates them into specific cellular outcomes. In B cells, somatic mutations in MyD88 trigger oncogenic NF-κB signaling independent of receptor stimulation, which leads to the development of B-cell malignancies. However, the exact molecular mechanisms and downstream signaling targets remain unresolved. We established an inducible system to introduce MyD88 to lymphoma cell lines and performed transcriptomic analysis (RNA-seq) to identify genes differentially expressed by MyD88 bearing the L265P oncogenic mutation. We show that MyD88L265P activates NF-κB signaling and upregulates genes that might contribute to lymphomagenesis, including CD44, LGALS3 (coding Galectin-3), NFKBIZ (coding IkBƺ), and BATF. Moreover, we demonstrate that CD44 can serve as a marker of the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) and that CD44 expression is correlated with overall survival in DLBCL patients. Our results shed new light on the downstream outcomes of MyD88L265P oncogenic signaling that might be involved in cellular transformation and provide novel therapeutical targets.
650    _2
$a lidé $7 D006801
650    12
$a NF-kappa B $x genetika $x metabolismus $7 D016328
650    _2
$a galektin 3 $x metabolismus $7 D037502
650    _2
$a myeloidní diferenciační faktor 88 $x genetika $x metabolismus $7 D053594
650    12
$a difúzní velkobuněčný B-lymfom $x patologie $7 D016403
650    _2
$a mutace $7 D009154
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a transkripční faktory bZIP $x genetika $7 D050976
650    _2
$a antigeny CD44 $x genetika $x metabolismus $7 D018960
650    _2
$a adaptorové proteiny signální transdukční $x metabolismus $7 D048868
655    _2
$a časopisecké články $7 D016428
700    1_
$a Anilkumar Sithara, Anjana $u Faculty of Science, University of Ostrava, 70100 Ostrava, Czech Republic $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
700    1_
$a Hofmanová, Lucie $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
700    1_
$a Žihala, David $u Faculty of Science, University of Ostrava, 70100 Ostrava, Czech Republic $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
700    1_
$a Radhakrishnan, Dhwani $u Faculty of Science, University of Ostrava, 70100 Ostrava, Czech Republic $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic $1 https://orcid.org/0000000298306635
700    1_
$a Vdovin, Alexander $u Faculty of Science, University of Ostrava, 70100 Ostrava, Czech Republic $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
700    1_
$a Knápková, Sofija $u Faculty of Science, University of Ostrava, 70100 Ostrava, Czech Republic $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
700    1_
$a Ševčíková, Tereza $u Faculty of Science, University of Ostrava, 70100 Ostrava, Czech Republic $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
700    1_
$a Chyra, Zuzana $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic $1 https://orcid.org/0000000348072532
700    1_
$a Jelínek, Tomáš $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic $1 https://orcid.org/0000000254679253
700    1_
$a Šimíček, Michal $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic $1 https://orcid.org/0000000323882723 $7 xx0247832
700    1_
$a Gullà, Annamaria $u Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy $u Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA 02215, USA $u Harvard Medical School, Boston, MA 02215, USA
700    1_
$a Anderson, Kenneth Carl $u Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA 02215, USA $u Harvard Medical School, Boston, MA 02215, USA
700    1_
$a Hájek, Roman $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic
700    1_
$a Hrdinka, Matouš $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic $u Department of Haematooncology, University Hospital Ostrava, 70800 Ostrava, Czech Republic $1 https://orcid.org/0000000229812825
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 24, č. 6 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36982699 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140900 $b ABA008
999    __
$a ok $b bmc $g 1924455 $s 1190002
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 24 $c 6 $e 20230315 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options